Premium
Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer
Author(s) -
Kaasa Stein,
Lund Eiliv,
Thorud Erik,
Hatlevoll Reidulv,
Høst Herman
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10<2443::aid-cncr2820671008>3.0.co;2-k
Subject(s) - medicine , etoposide , chemotherapy , lung cancer , mediastinum , radiation therapy , randomized controlled trial , cisplatin , surgery , oncology , lung , cancer
In a randomized clinical trial, 87 patients with inoperable, extensive non‐small cell lung cancer (NSCLC) were randomized to receive either combination chemotherapy (cisplatin at 70 mg/m 2 intravenously [IV] on day 1 and etoposide at 100 mg/m 2 IV on day 1 and 200 mg/m 2 orally on days 2 and 3) or symptomatic treatment. No statistically significant differences in survival time were found between the two treatment techniques. A major problem in the interpretation of the results was the use of semicurative radiation therapy (3000 to 4200 cGy) to the primary tumor and mediastinum, which was given with symptomatic intent. Three long‐term survivors were seen in the latter group.